Literature DB >> 29033057

Clinical inertia versus overtreatment in glycaemic management.

Kamlesh Khunti1, Melanie J Davies2.   

Abstract

Mesh：

Year:  2017        PMID： 29033057     DOI： 10.1016/S2213-8587(17)30339-X

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  9 in total

1.  Personalized medicine and proper dosage: Over- and undertreatment of chronic diseases endanger patients' health and strain public health systems.

Authors:  Anthi Trasta
Journal:  EMBO Rep       Date:  2018-02-27       Impact factor: 8.807

2.  Smart Pens Will Improve Insulin Therapy.

Authors:  David C Klonoff; David Kerr
Journal:  J Diabetes Sci Technol       Date:  2018-02-07

3.  Therapeutic Inertia: Still a Long Way to Go That Cannot Be Postponed.

Authors:  Manel Mata-Cases; Josep Franch-Nadal; Mònica Gratacòs; Dídac Mauricio
Journal:  Diabetes Spectr       Date:  2020-02

4.  Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes.

Authors:  Zoltán Taybani; Balázs Bótyik; Mónika Katkó; András Gyimesi; Tamás Várkonyi
Journal:  Diabetes Ther       Date:  2019-07-25       Impact factor: 2.945

Review 5.  Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.

Authors:  Yehuda Handelsman; Marcel H A Muskiet; Graydon S Meneilly
Journal:  Adv Ther       Date:  2019-10-23       Impact factor: 3.845

6.  Potential Risk of Overtreatment in Patients with Type 2 Diabetes Aged 75 Years or Older: Data from a Population Database in Catalonia, Spain.

Authors:  Manel Mata-Cases; Didac Mauricio; Jordi Real; Bogdan Vlacho; Laura Romera-Liebana; Núria Molist-Brunet; Marta Cedenilla; Josep Franch-Nadal
Journal:  J Clin Med       Date:  2022-08-31       Impact factor: 4.964

Review 7.  Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.

Authors:  Guntram Schernthaner; Naim Shehadeh; Alexander S Ametov; Anna V Bazarova; Fahim Ebrahimi; Peter Fasching; Andrej Janež; Péter Kempler; Ilze Konrāde; Nebojša M Lalić; Boris Mankovsky; Emil Martinka; Dario Rahelić; Cristian Serafinceanu; Jan Škrha; Tsvetalina Tankova; Žydrūnė Visockienė
Journal:  Cardiovasc Diabetol       Date:  2020-10-23       Impact factor: 9.951

8.  Factors associated with potential over- and undertreatment of hyperglycaemia and annual measurement of HbA1c in type 2 diabetes in norwegian general practice.

Authors:  Anh T Tran; Tore J Berg; Ibrahimu Mdala; Bjørn Gjelsvik; John G Cooper; Sverre Sandberg; Tor Claudi; Anne K Jenum
Journal:  Diabet Med       Date:  2021-01-07       Impact factor: 4.359

Review 9.  Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.

Authors:  Edward B Jude; Maciej T Malecki; Ricardo Gomez Huelgas; Martin Prazny; Frank Snoek; Tsvetalina Tankova; Dario Giugliano; Kamlesh Khunti
Journal:  Diabetes Ther       Date:  2022-03-11       Impact factor: 2.945
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.